Showing 1321-1330 of 5771 results for "".
- AEYE Health and Topcon Healthcare Announce Results of Autonomous DR Screening Studyhttps://modernod.com/news/aeye-health-partners-with-topcon-healthcare-announce-results-of-autonomous-dr-screening-technology/2482657/AEYE Health and Topcon Healthcare announced results of a recent study evaluating Topcon’s NW500 non-mydriatic retinal camera and AEYE Diagnostic Screening (AEYE-DS). In the study, the AEYE-DS AI technology, in conjunction with the Topcon
- At Angiogenesis, Regeneron Announces New Data for Eylea HD for RVO and Wet AMDhttps://modernod.com/news/at-angiogenesis-regeneron-announces-new-data-for-eylea-hd-for-rvo-and-wet-amd/2482656/Regeneron announced the first presentation of positive results from the phase 3 QUASAR trial investigating Eylea HD (aflibercept) 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions
- EyePoint Announces Positive 6-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for DMEhttps://modernod.com/news/eyepoint-announces-positive-6-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for-dme/2482649/EyePoint Pharmaceuticals announced positive 6-month results for the ongoing phase 2 VERONA clinical trial evaluating Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME). Duravyu is an investigational sustained delivery therapy delivering vorolanib, a selective tyros
- Qlaris Bio Announces Positive Topline Data From Two Phase 2 Trials of QLS-111 for Glaucomahttps://modernod.com/news/qlaris-bio-announces-positive-topline-data-from-two-phase-2-trials-of-qls-111-for-glaucoma/2482647/Qlaris Bio announced positive topline results from two US phase 2 clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). The trials (Osprey and Apteryx) successfully met all primary and secondary endpoints. Qlaris Bi
- Iantrek Announces First Commercial Cases of C.Rex Micro-Interventional System for Trabecular Outflow Enhancementhttps://modernod.com/news/iantrek-announces-first-commercial-cases-of-crex-micro-interventional-system-for-trabecular-outflow-enhancement/2482640/Iantrek announced the completion of the first commercial cases utilizing its C.Rex micro-interventional system for canal outflow enhancement in glaucoma surgery. Iantrek said the milestone marks the beginning of the company's pre-launch activities for the C.Re
- 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DMEhttps://modernod.com/news/4dmt-announces-positive-interim-data-from-4d-150-spectra-clinical-trial-in-dme/2482620/4D Molecular Therapeutics announced topline interim data from Part 1 of its SPECTRA clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The company said it has achieved alignment with the FDA on the registrational pathway for 4D-150 in DME, advancing its
- AbbVie and Regenxbio Announce Updates on the ABBV-RGX-314 Clinical Program in DR and Wet AMDhttps://modernod.com/news/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program-in-dr-and-wet-amd/2482618/AbbVie and Regenxbio announced updates to the ABBV-RGX-314 gene therapy clinical program. Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026. The co
- Rayner Announces Full Commercial Launch of RayOne Galaxy and RayOne Galaxy Torichttps://modernod.com/news/rayner-announces-full-commercial-launch-of-rayone-galaxy-and-rayone-galaxy-toric/2482617/After unveling the RayOne Galaxy and RayOne Galaxy Toric IOLs at the ESCRS congress in Barcelona, Rayner announced the full commercial release of the IOLs today. The launch comes following a large-scale multi
- Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Trial of Linsitinib in Patients with TEDhttps://modernod.com/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-trial-of-oral-small-molecule-linsitinib-in-patients-with-ted/2482614/Sling Therapeutics announced topline efficacy and safety data from the phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe Thyroid Eye Disease (TED). Linsitinib, Sling’s lead product candidate, is an oral small molecule, taken twice-daily
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the